Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,141 to 1,160 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. | Hered Cancer Clin Pract | 2022 | 35313928 | PubTator, text mining | PubMed |
| Double heterozygous mutation in RAD50 and ATM genes in a Peruvian family with five cancer types: a case report. | Rev Fac Cien Med Univ Nac Cordoba | 2022 | 35312250 | PubTator, text mining | PubMed |
| Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. | Ther Adv Med Oncol | 2022 | 35309086 | PubTator, text mining | PubMed |
| BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies. | Front Cell Dev Biol | 2022 | 35300412 | PubTator, text mining | PubMed |
| Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. | PLoS One | 2022 | 35294956 | PubTator, text mining | PubMed |
| Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. | Braz J Med Biol Res | 2022 | 35293552 | PubTator, text mining | PubMed |
| BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling. | Sci Rep | 2022 | 35292711 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients. | J Cancer | 2022 | 35281878 | PubTator, text mining | PubMed |
| Clinical and genomic features of Chinese lung cancer patients with germline mutations. | Nat Commun | 2022 | 35273153 | PubTator, text mining | PubMed |
| Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? | Int J Mol Sci | 2022 | 35269712 | PubTator, text mining | PubMed |
| Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies. | Int J Mol Sci | 2022 | 35269636 | PubTator, text mining | PubMed |
| DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks. | Molecules | 2022 | 35268641 | PubTator, text mining | PubMed |
| Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. | Cancers (Basel) | 2022 | 35267561 | PubTator, text mining | PubMed |
| The BRCA Gene in Epithelial Ovarian Cancer. | Cancers (Basel) | 2022 | 35267543 | PubTator, text mining | PubMed |
| Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. | Cancers (Basel) | 2022 | 35267439 | PubTator, text mining | PubMed |
| "It was a no-brainer": A qualitative study of factors driving previvors' decision-making when considering risk-reducing salpingectomy with delayed oophorectomy. | Gynecol Oncol Rep | 2022 | 35265744 | PubTator, text mining | PubMed |
| Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. | Sci Rep | 2022 | 35264596 | PubTator, text mining | PubMed |
| Establishment and validation of a prognostic model based on HRR-related lncRNAs in colon adenocarcinoma. | World J Surg Oncol | 2022 | 35264195 | PubTator, text mining | PubMed |
| TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. | J Clin Oncol | 2022 | 35263119 | PubTator, text mining | PubMed |
| Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer. | Oncol Lett | 2022 | 35261632 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=58